-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Encephalitic-alphavirus-IN-1
Category | Virus Protease |
Description | Encephalitic alphavirus-IN-1 has antiviral activity for VEEV and EEEV with EC50s of 0.24 μM and 0.16 μM, respectively. |
Product Information
Synonyms | Encephalitic alphavirus-IN-1|HY-145842|CS-0434183 |
Molecular Weight | 484.52 |
Molecular Formula | C27H25FN6O2 |
Canonical SMILES | CC1=NC=C(C=C1)C2=C3C(=CC(=C2)C#N)C(=O)N(C4C(=N3)N(CCN4C)C)C5=CC(=C(C=C5)OC)F |
Purity | ≥98% (HPLC) |
Density | 1.2±0.1 g/cm3 |
Solubility | In vitro: 10 mM in DMSO |
Appearance | Solid powder |
Storage | Store at -20°C |
Complexity | 906 |
Exact Mass | 484.20230222 |
Index Of Refraction | 1.637 |
In Vitro | Encephalitic alphavirus-IN-1 (1 and 5 μM; 18 hours) reduces substantial VEEV and EEEV in human brain primary neuronal cells. |
Target | EC50: 0.24 μM (VEEV), 0.16 μM (EEEV) |
XLogP3-AA | 2.9 |